NOVAVAX INC

NOVAVAX INC (NVAX) is a publicly traded US company. Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.

The company reports trailing twelve-month revenue of $139.51M and net loss of $9.49M.

Key metrics include a return on equity of 6.6%, a debt-to-equity ratio of -8.21.

Investors tracking NVAX can follow price movements, analyst estimates, and fundamental changes directly through FINOTAUR's research tools.